Antidiabetics Market (By Product: Insulin, Drug Class; By Patient Population: Pediatric, Adults, Geriatric; By Route of Administration: Oral, Infusion, Intravenous, Insulin Pump, Insulin Pen/Syringe) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033


The global antidiabetics market size was estimated at USD 98.20 billion in 2023 and is anticipated to reach around USD 227.50 billion by 2033 with a CAGR of 8.76% from 2024 to 2033. The increasing geriatric population and the changing lifestyle habits are driving the growth of the antidiabetics market.

Antidiabetics Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • North America has held the largest revenue share of around 39% in 2023.
  • Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
  • By product, the insulin segment dominated the antidiabetics market with the highest share in 2023.
  • By product, the drug class segment is observed to grow at a significant rate during the forecast period.
  • By patient population, the geriatric segment held the dominating share of the market in 2023.
  • By route of administration, the oral segment led the market in 2023. The segment is observed to sustain the position.
  • By route of administration, the insulin pen/syringe segment is observed to witness the fastest rate of expansion throughout the forecast period.

Antidiabetics Market Size in the U.S. 2024 To 2033

The U.S. antidiabetics market size was valued at USD 30.26 billion in 2023 and is expected to hit around USD 70.09 billion by 2033, poised to grow at a CAGR of 8.80% from 2024 to 2033.

U.S. Antidiabetics Market Size 2024 to 2033

North America dominated the antidiabetics market with the largest share in 2023. North America has one of the highest prevalence rates of diabetes globally, with a significant portion of the population affected by the disease. The region's sedentary lifestyle, unhealthy dietary habits, and increasing rates of obesity contribute to the growing diabetes burden, driving the demand for antidiabetic medications. North America is home to some of the world's leading pharmaceutical companies, which play a pivotal role in driving innovation and market expansion in the antidiabetics sector. These companies invest heavily in research and development, clinical trials, and marketing efforts to introduce new antidiabetic drugs and expand their market share.

There is a growing awareness and emphasis on diabetes prevention, early detection, and management in North America. Healthcare initiatives, public awareness campaigns, and educational programs aimed at promoting healthy lifestyle choices and diabetes management contribute to higher diagnosis rates and treatment-seeking behavior.

Antidiabetics Market Share, By Region, 2023 (%)

Asia Pacific is expected to stand as the second largest marketplace while expanding at the fastest pace in the antidiabetics market during the forecast period. Asia Pacific is home to a vast population, including countries with some of the highest diabetes prevalence rates globally, such as India and China. The sheer size of the population contributes to a substantial market for antidiabetic drugs and therapies. With improving healthcare infrastructure and rising disposable incomes, there has been a corresponding increase in healthcare spending across Asia Pacific. As a result, more individuals have access to healthcare services, including diagnosis and treatment for diabetes, driving the demand for antidiabetic drugs.

  • According to the latest study by the Lancet, it is estimated that about 11.4% of the 101 million people in India are affected by diabetes.
  • As per the Commissioned by the Health Ministry about 136 million or 15.3% of the Indian population is pre-diabetic.
  • According to the IDF, it is estimated that the China is having 140.5 and 147.2 million diabetes patient and India will have 101.0 and 134.2 million of diabetes patients by 2030 and 2045 respectively.

Governments in Asia Pacific countries have implemented favorable regulatory frameworks for pharmaceutical products, including antidiabetics. Streamlined approval processes and market access policies encourage innovation, competition, and investment in the antidiabetics market. Economic development and urbanization in Asia Pacific have led to lifestyle changes characterized by reduced physical activity, increased consumption of processed foods, and higher stress levels, all of which are risk factors for diabetes. Urban areas, in particular, experience a higher prevalence of diabetes, driving the demand for antidiabetic treatments.

Antidiabetics Market Overview

The antidiabetics market refers to the pharmaceutical industry segment dedicated to the research, development, manufacturing, and distribution of medications used in the treatment of diabetes mellitus. Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels over a prolonged period, resulting from either inadequate insulin production, ineffective insulin utilization, or both.

The antidiabetics market offers medications that aim to regulate blood glucose levels and manage the symptoms of diabetes to prevent complications such as cardiovascular disease, kidney failure, neuropathy, and blindness. These medications work through various mechanisms, including increasing insulin sensitivity, stimulating insulin production, inhibiting glucose absorption, and promoting glucose excretion.

Growth Factors

  • The rising geriatric population and the growing prevalence of unhealthy lifestyles are driving the growth of the market.
  • The antidiabetics market is observed to be driven with the rising investments in research and development activities.
  • The rising glucose intolerance in the population and the growing prevalence of type 2 diabetes in the younger population also enhance the growth of the market.
  • The rising government initiatives for controlling the growing number of diabetes patients with the awareness campaign by the various regional governments is driving the growth of the antidiabetics market.

Antidiabetics Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 8.76%
Global Market Size in 2023 USD 98.20 Billion
Global Market Size by 2033 USD 227.50 Billion
U.S. Market Size in 2023 USD 30.26 Billion
U.S. Market Size by 2033 USD 70.09 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product, By Patient Population, and By Route of Administration
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Antidiabetics Market Dynamics

Driver: Government initiatives for controlling diabetes

Multiple government initiatives taken for controlling the prevalence of diabetes acts as a major driver for the antidiabetics market. Government initiatives often include public health awareness campaigns that educate individuals about diabetes prevention, early detection, and management. These campaigns raise awareness about the importance of lifestyle modifications, regular screening, and adherence to treatment regimens, thereby increasing the demand for antidiabetic medications.

Some governments subsidize healthcare services, including medications for chronic conditions like diabetes, to make them more accessible and affordable to the population. Subsidies or reimbursement schemes reduce out-of-pocket expenses for patients, encouraging adherence to prescribed treatment regimens and boosting the uptake of antidiabetic medications. Government funding for diabetes research stimulates innovation in the development of new antidiabetic drugs and treatment modalities. Research grants and funding support clinical trials, drug discovery efforts, and technology advancements in diabetes management, leading to the introduction of novel therapies and treatment options in the market.

Restraint: Regulatory hurdles

The requirement of regulatory approvals for antidiabetics drugs creates a significant restraint for the antidiabetics market. Regulatory agencies impose rigorous standards and requirements for the approval of new antidiabetic drugs and therapies. Companies must conduct extensive preclinical and clinical trials to demonstrate safety, efficacy, and quality, which can be time-consuming and resource intensive. Regulatory agencies require ongoing monitoring and reporting of adverse events associated with antidiabetic drugs to ensure patient safety. Companies must establish robust pharmacovigilance systems to track and assess the safety and effectiveness of their products, adding further regulatory burdens and potential liabilities.

Opportunity: Technological advancements in drug formulation

The integration of technologies in diabetes drug development is creating a opportunity for the growth of the antidiabetics market. Advancements in drug formulation technologies enable the customization and individualization of antidiabetic therapies based on patient-specific factors such as genetics, metabolism, and disease progression. This personalized approach to treatment enhances therapeutic efficacy and minimizes adverse effects, resulting in optimized patient care. echnological advancements enable the exploration of alternative routes of administration for antidiabetic drugs, such as inhalation, transdermal patches, and buccal delivery. These non-traditional delivery methods offer advantages such as rapid onset of action, reduced systemic side effects, and improved patient acceptance.

Product Insights

The insulin segment dominated the antidiabetics market with the largest share in 2023. Insulin is a critical treatment option for individuals with diabetes, particularly those with type 1 diabetes who require insulin injections to manage their condition. With the global prevalence of diabetes rising steadily, the demand for insulin has increased substantially. The development of insulin delivery devices, such as insulin pens, pumps, and continuous glucose monitoring systems, has improved the convenience and ease of insulin administration for patients.

These technological advancements have expanded the accessibility and utilization of insulin therapy. While type 2 diabetes is initially managed through lifestyle modifications and oral medications, many individuals eventually require insulin therapy as the disease progresses. With the rising incidence of type 2 diabetes worldwide, the demand for insulin among this patient population has also surged.

The drug class segment is expected to witness a significant growth rate in the antidiabetics market during the forecast period. The Biguanides, GLP-Agonists, Thiazolidinediones, Sulphonylureas, SGLT-2, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, Meglitinides are sub-segments under the drug class segment. The rising demand for diabetes treatment along with the latest product launches promotes the expansion of the segment.

Patient Population Insights

The geriatric segment held the dominating share of the antidiabetics market in 2023. Elderly individuals often have multiple risk factors for diabetes, including obesity, a sedentary lifestyle, and comorbid conditions such as hypertension and cardiovascular disease. These factors contribute to a higher incidence of diabetes among older adults and a greater need for antidiabetic treatment. Aging is associated with changes in metabolism, insulin sensitivity, and pancreatic function, which can lead to the development or worsening of diabetes in older adults. As a result, elderly individuals may require more intensive management of their diabetes with antidiabetic medications.

Route of Administration Insights

The oral segment led the market with the largest share in 2023. Oral antidiabetic medications offer a convenient and non-invasive treatment option for patients with diabetes. Compared to other forms of treatment such as insulin injections or implantable devices, oral medications are easier to administer and can be taken orally, often with meals. The oral antidiabetics market offers a wide range of medication options, including various classes such as biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT-2 inhibitors, and others. This diversity allows healthcare providers to tailor treatment regimens to individual patient needs and preferences.

In many healthcare systems, oral antidiabetic medications are cost-effective compared to other forms of treatment such as insulin therapy or surgical interventions. This affordability makes oral medications accessible to a larger population of patients with diabetes, driving market demand and dominance.

The insulin pen/syringe segment is observed to witness the fastest rate of expansion in the antidiabetics market during the forecast period. Insulin pens and syringes offer a convenient and user-friendly method for administering insulin. Compared to traditional vial and syringe methods, insulin pens require less manual dexterity and are preferred by many patients, especially those with limited mobility or visual impairment. Insulin pens and syringes are designed for single-patient use, reducing the risk of contamination and infection transmission compared to multi-dose vials. This enhances patient safety and reduces the likelihood of needle-stick injuries.

Recent Development

  • In February 2023, IOL Chemicals and Pharmaceuticals Ltd, a leading pharmaceutical company’s share increased 12.1% and noticed the 8.25% higher at Rs 437.3 piece during the intraday session. The price of stock increased after the announcement of the antidiabetic drug ‘Metformin Hydrochloride’ approved by China’s drug supervisor.
  • In February 2024, Boehringer Ingelheim launched an antidiabetic drug in India for the treatment of chronic kidney dieases getting approval from the Central Drugs Standard Control Organization (CDSCO).
  • In January 2024, Glenmark Pharmaceuticals launched the antidiabetic drug a biosimilar of the Liraglutide a famous antidiabetic drug. The drug gets approval from the Drug Controller General of India (DCGI).
  • In January 2022, the Danish Drug Maker, Novo Nordisk introduce the launch of anti-diabetics drug semaglutide in India for the Type 2 diabetes treatment.

Antidiabetic Market Companies

  • Sanofi-Aventis
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Oramed Pharmaceuticals
  • Boehringer Ingelheim
  • Merck & Co. Inc.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Halozyme Therapeutics
  • Pfizer

Segments Covered in the Report

By Product

  • Insulin
    • Rapid Acting
    • Long Acting
    • Premixed Insulin
    • Short Acting
  • Drug Class
    • Biguanides
    • GLP-Agonists
    • Thiazolidinediones
    • Sulphonylureas
    • SGLT-2
    • Alpha-Glucosidase Inhibitors
    • DPP-4 Inhibitors
    • Meglitinides

By Patient Population

  • Pediatric
  • Adults
  • Geriatric

By Route of Administration

  • Oral
  • Infusion
  • Intravenous
  • Insulin Pump
  • Insulin Pen/Syringe

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

How big is the antidiabetics industry?
The global antidiabetics market size is expected to increase USD 227.50 billion by 2033 from USD 227.50 billion in 2023.
What is the growth rate of the antidiabetics industry?
The global antidiabetics market will register growth rate of 8.76% between 2024 and 2033.
Who are the prominent players operating in the antidiabetics market?
The major players operating in the antidiabetics market are Sanofi-Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals, Boehringer Ingelheim, Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics, Pfizer, and Others.
Which are the driving factors of the antidiabetics market?
The driving factors of the antidiabetics market are the government initiatives for controlling diabetes, rising investments in research and development activities, growing number of diabetes patients.
Which region will lead the global antidiabetics market?
North America region will lead the global antidiabetics market during the forecast period 2024 to 2033.

PROCEED TO BUY :

   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample